Aleksandra Pastrak - Transition Therapeutics Insider

Transition Therapeutics Inc -- Canada Stock  

CAD 1.93  0.00  0.00%

VP of Clinical Devel. and Medical Officer

Dr. Aleksandra Pastrak is Vice President Clinical Development and Medical Officer of Transition Therapeutics Inc. Dr. Pastrak was with Transition since 1999 and served as VP Research since 2005 until she was appointed VP Clinical Development in 2011. With her expertise in medicine and pharmacology she has made an invaluable contribution to the development of our clinical programs for various therapeutic products
Age: 45  VP Since 2011  Ph.D    
Pastrak holds an MD from the School of Medicine at the University of Belgrade and M.Sc. and Ph.D. degrees in Clinical Pharmacology from the University of Toronto.

Management Efficiency

The company has return on total asset (ROA) of (34.83) % which means that it has lost $34.83 on every $100 spent on asset. This is way below average.

Similar Executives

Found 1 records

VP Since

Jake LawrenceThe Bank of Nova Scotia

Entity Summary

Transition Therapeutics Inc., a biopharmaceutical company, researches and develops therapeutic agents for disease indications primarily in Canada. Transition Therapeutics Inc (TTH) is traded on Toronto Stock Exchange in Canada. It is located in Toronto, ON MG L and employs 18 people.

Did you try this?

Run Stock Tickers Now

Stock Tickers

Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Hide  View All  NextLaunch Stock Tickers
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Transition Therapeutics Inc to your portfolio

Top Management

Transition Therapeutics Leadership Team
Christopher Henley, Director
Gary Pace, Director, Ph.D
Carl Damiani, COO
Bruce Connop, VP, Ph.D
Louis Alexopoulos, Executive
Nicole Rusaw, CFO
Aleksandra Pastrak, VP, Ph.D
Paul Baehr, Director
Michael Ashton, Director
Tony Cruz, Chairman

Stock Performance

Transition Therapeutics Performance Indicators